A high-throughput diagnostic for relapsing liver malaria

The Problem

- Endemic countries throughout the Asia-Pacific have committed to eliminate malaria by 2030
- *P. vivax* is very difficult to eliminate because dormant liver stages relapse and cause 79% of new infections
- Current diagnostic approaches cannot detect liver stages

The Solution

- A novel Luminex Assay to detect recent (≤270 days) *P. vivax* infection (Longley 2020 Nature Medicine)
- Recently-infected individuals can then be treated with drugs that target malaria liver stages
- Modelling shows that such a “test and treat” approach could accelerate *P. vivax* elimination (clinical validation ongoing)

Our Program

- Patent-protected panel of *P. vivax* serological exposure markers; all IP owned by WEHI
- Development of a fully standardised and quality-controlled Luminex-based reference assay is underway
- Looking to licence technology to an existing diagnostics company or create spinout for future acquisition

Underlying principle



Diagnostic Performance



Our Team

Prof Ivo Mueller, Population Health and Immunity
Dr Rhea Longley, Population Health and Immunity

Victoria Jameson, PhD, Business Development Lead
jameson.v@wehi.edu.au